Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-5-1
|
pubmed:abstractText |
The present study was performed to evaluate the ability of KR-30032 and KR-30035 to overcome multidrug resistance (MDR) by measuring the cytotoxicity and the accumulation rate of rhodamine. Additionally, the adverse cardiac toxicity of KR-30032 and KR-30035 was evaluated by measuring the changes of tension in isolated rat aorta and left ventricular pressure (LVP) in guinea pig heart. KR-30035 potentiated the paclitaxel-induced cytotoxicity to HCT15 [P-glycoprotein (P-gp)-expressed cells] to over 15-fold greater than that of verapamil and KR-30032 was equipotent with verapamil (EC50: 0.07, 5.0 and 3.3 nM at 1.0 microg/ml). KR-30032 and KR-30035 were without effect on cytotoxicity to SK-OV-3 cells (P-gp-non-expressing cells), as well as to tamoxifen-induced cytotoxicity in the above cell types. Maximal rhodamine accumulation rates with KR-30032, KR-30035 and verapamil were 290, 291 and 271% in HCT15 cells; and 451, 970 and 440% in HCT15/CL02 cells, respectively. KR-30032 and KR-30035 were 20- to 25-fold less potent than verapamil in relaxing aorta (EC50: 8.13, 6.40 and 0.32 microM, respectively) and were 12- to 35-fold less potent than verapamil in decreasing LVP in isolated hearts (EC50: 41.8, 14.1 and 1.2 microM, respectively). The results of this study suggest that KR-30032 and KR-30035 are active modulators of MDR with potentially minimal cardiovascular toxicity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorescent Dyes,
http://linkedlifedata.com/resource/pubmed/chemical/Indenes,
http://linkedlifedata.com/resource/pubmed/chemical/Rhodamines,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydronaphthalenes,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0959-4973
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
157-65
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9510502-Adenocarcinoma,
pubmed-meshheading:9510502-Animals,
pubmed-meshheading:9510502-Antineoplastic Agents,
pubmed-meshheading:9510502-Calcium Channel Blockers,
pubmed-meshheading:9510502-Drug Resistance, Multiple,
pubmed-meshheading:9510502-Drug Resistance, Neoplasm,
pubmed-meshheading:9510502-Fluorescent Dyes,
pubmed-meshheading:9510502-Guinea Pigs,
pubmed-meshheading:9510502-Humans,
pubmed-meshheading:9510502-Indenes,
pubmed-meshheading:9510502-Rats,
pubmed-meshheading:9510502-Rhodamines,
pubmed-meshheading:9510502-Tetrahydronaphthalenes,
pubmed-meshheading:9510502-Tumor Cells, Cultured,
pubmed-meshheading:9510502-Verapamil
|
pubmed:year |
1998
|
pubmed:articleTitle |
Reversal of multidrug resistance by novel verapamil analogs in cancer cells.
|
pubmed:affiliation |
Screening and Toxicology Research Center, Korea Research Institute of Chemical Technology, Yusong, Korea.
|
pubmed:publicationType |
Journal Article
|